

P38 KINASE INHIBITORS Report

Author: Philippe Tramoy

Date: 1 February 2010

"Copyright 2010 CBDM.T SARL - Market and Business Intelligence. All rights reserved. Any unauthorized use or disclosure is prohibited. The information herein was obtained from various sources; we do not guarantee its accuracy or completeness. This research report is prepared for general circulation and is circulated for general information only. It does not have regard to specific investment objectives, financial situation and the particular needs of any particular person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any securities or investment and trading strategies discussed or recommended in this report and should understand that the statements regarding future prospects may not be realized. Investors should note that income from such securities, if any, may fluctuate and that each security's price or value may rise or fall. Accordingly, investors may receive back less than originally invested. Past performance is not necessarily a guide to future performance. Neither the information nor any opinion expressed constitutes an offer to buy or sell any securities or options or futures contracts. CBDM.T - Market and Business Intelligence accepts no responsibility or liability whatsoever for any expense, loss or damages arising out of or in any way connected with the use of all or any part of this report. CBDM.T SARL does not have long or short position in any securities or options of this issue(s)."

Table of Content

I.	Presentation – General Information	2
II.	Psoriasis.....	3
	Market Analysis	3
	Treatment Trends.....	4
	New Treatments For Psoriasis.....	4
III.	Arthritis.....	4
IV.	Originators – In-Licensors – Partners	5
	Originators.....	5
	AMGEN INC.....	5
	BAYER AG.....	5
	PFIZER INC	5
	Partners	5
	BRISTOL-MYERS SQUIBB CO	5
	PHARMACOPEIA INC (a subsidiary of LIGAND PHARMACEUTICALS INC).....	6
V.	Clinical Trials.....	7
	Clinical Trial List	7
VI.	SWOT Analysis.....	9
VII.	News.....	10
	PHASE 2 CLINICAL STUDIES INITIATED FOR A NOVEL THERAPEUTIC CANDIDATE IDENTIFIED THROUGH PHARMACOPEIA COLLABORATION.....	10
	PHARMACOPEIA DRUG DISCOVERY, INC. AND BRISTOL-MYERS SQUIBB COMPANY ADVANCES RHEUMATOID ARTHRITIS CANDIDATE WITH SECOND NOVEL P38 KINASE INHIBITOR IN CANADIAN CLINICAL TRIAL	11